Table 3.
Incidence of treatment-related adverse events attributed to cabozantinib.
| Cabozantinib 20 mg plus avelumab (n = 3) | Cabozantinib 40 mg plus avelumab (n = 3) | Cabozantinib 60 mg plus avelumab (n = 6) | Total (n = 12) | |||||
|---|---|---|---|---|---|---|---|---|
| Adverse events, n (%) | Any grade |
Grades 3-5 |
Any grade |
Grades 3-5 |
Any grade |
Grades 3-5 |
Any grade |
Grades€ 3-5 |
| Diarrhea | 3 (100) | 1 (33.3) | 1 (33.3) | 6 (100) | 1 (16.7) | 10 (83.3) | 2 (16.7) | |
| Palmar-plantar erythrodysesthesia syndrome | 1 (33.3) | 2 (66.7) | 5 (83.3) | 1 (16.7) | 8 (66.7) | 1 (8.3) | ||
| Thromboembolic events | 1 (33.3) |
1 (33.3) |
2 (66.7) | 2 (66.7) | 5 (83.3) | 2 (33.3) | 8 (58.3) | 5 (25) |
| Dysgeusia | 1 (33.3) | 2 (66.7) | 4 (66.7) | 7 (58.3) | ||||
| Mucositis oral | 1 (33.3) | 1 (33.3) | 4 (66.7) | 1 (16.7) | 6 (50) | 1 (8.3) | ||
| Anorexia | 1 (33.3) | 1 (33.3) | 3 (50) | 1 (16.7) | 5 (41.7) | 1 (8.3) | ||
| Fatigue | 2 (66.7) | 3 (50) | 1 (16.7) | 5 (41.7) | 1 (8.3) | |||
| Hypokalemia | 1 (33.3) | 3 (50) | 4 (33.3) | |||||
| Hypothyroidism | 1 (33.3) | 1 (33.3) | 3 (50) | 5 (41.7) | ||||
| Vomiting | 3 (50) | 3 (25) | ||||||
| ALT increased | 2 (33.3) | 1 (16.7) | 2 (16.7) | 1 (8.3) | ||||
| AST increased | 1 (33.3) | 2 (33.3) | 1 (16.7) | 3 (25) | 1 (8.3) | |||
| Hoarseness | 2 (33.3) | 2 (16.7) | ||||||
| Hypertension | 1 (33.3) | 1 (33.3) | 2 (33.3) | 2 (33.3) | 3 (25) | 3 (25) | ||
| Weight loss | 1 (33.3) | 1 (33.3) | 2 (33.3) | 4 (33.3) | ||||
| Abdominal pain | 1 (33.3) | 1 (16.7) | 2 (16.7) | |||||
| Dry mouth | 1 (33.3) | 1 (16.7) | 2 (16.7) | |||||
| Dry skin | 1 (33.3) | 1 (16.7) | 2 (16.7) | |||||
| Epistaxis | 1 (16.7) | 1 (8.3) | ||||||
| Upset stomach | 1 (16.7) | 1 (8.3) | ||||||
| Cold Sores | 1 (16.7) | 1 (8.3) | ||||||
| Headache | 1 (16.7) | 1 (8.3) | ||||||
| Hyponatremia | 1 (16.7) | 1 (16.7) | 1 (8.3) | 1 (8.3) | ||||
| Insomnia | 1 (16.7) | 1 (8.3) | ||||||
| Nail discoloration | 1 (16.7) | 1 (8.3) | ||||||
| Nausea | 1 (33.3) | 1 (16.7) | 2 (16.7) | |||||
| Oral dysesthesia | 1 (33.3) | 1 (16.7) | 2 (16.7) | |||||
| Pruritus | 1 (16.7) | 1 (8.3) | ||||||
| Rash maculo-papular | 1 (33.3) | 3 (100) | 1 (33.3) | 1 (16.7) | 5 (41.7) | 1 (8.3) | ||
| Skin irritation | 1 (16.7) | 1 (8.3) | ||||||
| Skin wound | 1 (16.7) | 1 (8.3) | ||||||
| Skin hyperpigmentation | 1 (16.7) | 1 (8.3) | ||||||
| Skin ulceration | 1 (16.7) | 1 (8.3) | ||||||
| Anemia | 1 (33.3) | 1 (33.3) | 1 (8.3) | 1 (8.3) | ||||
| Arthralgia | 1 (33.3) | 1 (8.3) | ||||||
| Bruising | 1 (33.3) | 1 (8.3) | ||||||
| Cough | 1 (33.3) | 1 (8.3) | ||||||
| Dizziness | 1 (33.3) | 1 (8.3) | ||||||
| Gastroesophageal reflux disease | 1 (33.3) | 1 (8.3) | ||||||
| Muscle cramping | 1 (33.3) | 1 (8.3) | ||||||
| Hand-foot sensitivity | 1 (33.3) | 1 (8.3) | ||||||
| Face rash | 1 (33.3) | 1 (8.3) | ||||||
| Skin hypopigmentation | 1 (33.3) | 1 (8.3) | ||||||
| Stomach pain | 1 (33.3) | 1 (8.3) | ||||||
€ = there were no grade 5 events in any patient.